Phathom Pharmaceuticals

CompanyUnited States

RORWikidata

Phathom Pharmaceuticals develops 2 assets, the furthest approved (vonoprazan in heartburn). Mostly small molecule acting on ATP4A and ATP4B; based in the United States.

2
Assets
Furthest stage
Approved
14
Trials
12
Signals

Pipeline

2
  • vonoprazan

    Blocks gastric proton pumps competitively with potassium to suppress stomach acid secretion.

    Approved, Small molecule, ATP4A, ATP4B, heartburn, Erosive Esophagitis

  • VOQUEZNA Triple Pak

    Combines vonoprazan-mediated gastric acid suppression with amoxicillin and clarithromycin to eradicate Helicobacter pylori.

    Approved, Small molecule, Helicobacter pylori infection, gastric cancer (Phase 3)

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Trials16
  • Deals4
  • People20
  • Signals15
  • Similar companies6

Intelligence